← Back to Search

Local Anesthetic

Mg and Bupivacaine for Opioid Use Disorder

N/A
Waitlist Available
Research Sponsored by Wayne State University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Patients undergoing unilateral primary total knee arthroplasty with spinal anesthetic and MAC followed by a unilateral adductor canal block with ultrasound guidance.
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 24 hours after surgery
Awards & highlights

Study Summary

This trial will compare the use of two different drugs to see if one can result in decreased opioid consumption and improved pain management for patients after total knee arthroplasty.

Eligible Conditions
  • Opioid Use Disorder
  • Postoperative Pain

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~the second 24 hours after surgery
This trial's timeline: 3 weeks for screening, Varies for treatment, and the second 24 hours after surgery for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Total opioid consumption (oral morphine equivalents) in the first 24 hours after surgery
Total opioid consumption (oral morphine equivalents) in the second 24 hours after surgery
Visual analog scale (VAS) pain score at 24 hours after surgery
+1 more
Secondary outcome measures
Overall patient satisfaction in first 48 hours after surgery
Percentage of incidence of post-operative nausea/ vomiting in first 48 hours after surgery

Trial Design

2Treatment groups
Active Control
Group I: Mg and BupivacaineActive Control1 Intervention
Patients in this arm (selected randomly) will receive an ultrasound-guided adductor canal block (ACB) with 30cc of 0.25% bupivacaine and 150mg of Mg.
Group II: Buprenorphine and BupivacaineActive Control1 Intervention
Patients in this arm (selected randomly) will receive an ultrasound-guided adductor canal block (ACB) with 30cc of 0.25% bupivacaine and 300 mcg of buprenorphine.

Find a Location

Who is running the clinical trial?

Wayne State UniversityLead Sponsor
307 Previous Clinical Trials
108,364 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
~29 spots leftby Apr 2025